MHRA (UK)
OTHER
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
Published: 10/12/2026Detected: 10/12/2026
Summary preview
Initiates a Class 2 recall of Pedmarqsi 80 mg/mL solution for infusion for specified batches due to a risk of particulate matter detected during routine stability investigations.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountpediatrics
manufacturing
quality
safety
labeling
#MHRA
#recall
#Class 2
#particulate matter
#stability investigations
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/01310/9/2026
- Field Safety Notices for October 202610/9/2026
- Field Safety Notices: 8 -12 June 202610/9/2026
- Field Safety Notices: 28 September 2026 to 2 October 202610/9/2026
- Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/4110/5/2026